Additionally, resistance mechanisms include the PI3K/AKT/mTOR pathway, which is dysregulated in 22% of BRAF inhibitor-resistant melanomas characterized by increased expression of the AKT protein [36]. The gene discussed is PIK3CA; the disease is melanoma.